Skip to Content

TriHIBit – Diphtheria, Tetanus Toxoid, and Acellular Pertussis with Haemophilus b Conjugate Vaccine (DTaP with Haemophilus b Conjugate)

Last Updated: April 8, 2011
Status: Discontinued

Products Affected - Description

TriHIBit Vaccine, Sanofi Pasteur
0.6 mL single-dose vial of Tripedia plus 1 single-dose vial of ActHIB (lyophilized haemophilus b vaccine), package of 5 of each vial (NDC 49281-0597-05) – discontinued

Reason for the Shortage

Sanofi Pasteur discontinued their Tripedia and TriHIBit vaccines in 2011.

Estimated Resupply Dates

Sanofi Pasteur discontinued TriHIBit vaccine and Tripedia vaccine, a component of TriHIBit. Supplies of TriHIBit are no longer available.

Alternative Agents & Management

  • DTaP and Tdap vaccines both contain diphtheria, tetanus toxoid, and acellular pertussis. DTaP and DTaP combination vaccines are recommended for use in infants and children under 7 years of age. Tdap vaccines (eg, Adacel, Boostrix) are recommended for use in adolescents and adults 10 to 64 years of age.
  • Sanofi Pasteur has available ActHIB lyophilized vaccine (NDC 49281-0545-05) and Pentacel vaccine (NDC 49281-0510-05). ActHIB lyophilized vaccine is haemophilus b conjugate vaccine and Pentacel is DTaP and inactivated poliovirus vaccine combined with haemophilus b conjugate vaccine.
  • There are no available combination vaccines containing only DTaP and haemophilus b conjugate.

Related Shortages


April 8, 2011, University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.